A gentler transplant drug kept kidneys working better — and patients feeling better

For people living with a transplanted kidney, the standard anti-rejection drug can itself strain the organ it protects. In the Phase 2 BESTOW trial, a new antibody treatment called tegoprubart preserved kidney function better than the standard tacrolimus — function held steadier from the first month and was significantly better at 18 months — and patients reported greater improvements in quality of life across all five measured areas at one year. The findings, from 127 transplant recipients, were presented at ASN Kidney Week 2026.

SDG 3 · Good health and well-being — Mechanism: tech innovation